Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.

Authors

Bradley C. Leibovich

Mayo Clinic, Rochester, MN

Bradley C. Leibovich , Tanner Miest , Paul R Young , Mark L. Gonzalgo , Stephen A. Boorjian , Matthew K. Tollefson , R. Jeffrey Karnes , Igor Frank , Timothy D. Lyon , Tessa Kroeninger , Shruthi Naik , Monica Reckner , Rosa M Diaz , Stephen Kaesshaefer , Ena Whitelaw , Bethany A Brunton , Alysha Newsom , Nandakumar Packiriswamy , Kah Whye Peng , Alice Susannah Bexon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Clinical Trial Registration Number

NCT03171493

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3172)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3172

Abstract #

TPS3172

Poster Bd #

236

Abstract Disclosures

FEATURED

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.

Authors

Bradley C. Leibovich

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

Poster

Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.

Poster

Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Poster

Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).